![Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial | tctmd.com Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial | tctmd.com](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/styles/large_slide_teaser/public/2012-08/113310.png?itok=34UiOi_Q)
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial | tctmd.com
methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate sulfate | C16H18ClNO6S2 | CID 16757820 - PubChem
![Frontiers | PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel—A Systematic Review and Meta-Analysis Frontiers | PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel—A Systematic Review and Meta-Analysis](https://www.frontiersin.org/files/Articles/417222/fphys-09-01550-HTML/image_m/fphys-09-01550-g001.jpg)